BEIJING, June 22 (Xinhua)-- Shanghai Fosun Pharmaceutical (Group) Co.,(600196.SH;02196.HK) announced that its subsidiary Shanghai Henlius Biotech, Inc. authorized Accord with exclusive merchandizing right of the recombinant anti-HER2 humanized monoclonal antibodies for injection in specific areas in the world.
The product is used in the treatment of breast cancer indications, which has been in phase III clinical trials in China, Ukraine, Poland and other countries.
According to a company filing, Accord shall pay Shanghai Henlius Biotech,Inc. up to 40.50 million U.S. dollars of down payment and other fees. The permission area includes the European region, parts of the Middle East and North Africa, and some CIS countries.
Accord is a global pharmaceutical company that specializes in the development, manufacturing and sale of generic and biosimilar in North America, Europe, Australia, Asia Pacific and other regions, and has a strong sales network.
Shanghai Henlius Biotech, Inc. is a joint venture formed by Shanghai Fosun Pharmaceutical (Group) Co., Ltd. and Henlius Biopharmaceuticals Co., Ltd. in December 2009. The company focuses on the development, production and commercialization of mAb biosimilar drugs, bio-betters and novel mAbs using cutting-edge technology. (Edited by Ma Xin,maxin11@xinhua.org)
A single purchase
